Mubadala Investment Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.2M Sell
233,437
-23,196
-9% -$1.35M 0.07% 9
2025
Q4
$13.8M Buy
256,633
+74,961
+41% +$3.61M 0.08% 13
2025
Q3
$8.19M Buy
181,672
+117,020
+181% +$5.47M 0.05% 16
2025
Q2
$2.99M Sell
64,652
-4,443
-6% -$218K 0.02% 36
2025
Q1
$4.21M Buy
+69,095
New +$4.03M 0.02% 15

Other funds holding BMY

Mubadala Investment Company's BMY Position: Q1 2026 in Review

Mubadala Investment Company reduced its Bristol-Myers Squibb (BMY) stake by 9% in Q1 2026, selling an estimated $1.35M and leaving 233,437 shares worth $14.2M. The position accounts for 0.07% of the portfolio, ranked #9.

Mubadala Investment Company first reported a position in BMY in Q1 2025 and has held it in 5 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Mubadala Investment Company held 233,437 shares of Bristol-Myers Squibb worth $14.2M as of Q1 2026.
  • Mubadala Investment Company sold 23,196 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.35M.
  • Bristol-Myers Squibb made up 0.07% of Mubadala Investment Company's portfolio in Q1 2026, its #9 holding.
  • Mubadala Investment Company first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 5 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Mubadala Investment Company's 13F filing for Q1 2026, filed 15 May 2026.